Disclosure of pharmacokinetic drug results to understand nonadherence
about
Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyStated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.Adherence and the Lie in a HIV Prevention Clinical Trial.Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.Acceptability and use of a dapivirine vaginal ring in a phase III trial.Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study.Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa.Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography.Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling.Collateral benefits: how the practical application of Good Participatory Practice can strengthen HIV research in sub-Saharan Africa
P2860
Q27300707-CF5B2EE8-89E4-4B09-89CD-7457A05F5F92Q36952395-3D808264-133B-4ADD-BD77-0A16DB6B6707Q37159067-B3DD1E3D-E8C1-4798-AE71-2B1AE8BAABB0Q37736062-42E39DB9-CDB0-4C6B-AA87-01DAE7474EB4Q38767384-15AD4E3D-461A-411A-B9C1-335D7E735914Q38794119-02FF9EC0-2B95-458C-A419-58B61CA38D2BQ38849514-6F29BCA1-0EC7-4A47-B0A0-F5B86295281AQ38850472-6929A646-BE82-4406-924F-31E30D8BEABBQ38851078-E34F8A57-5244-4833-8269-EDA0F1FF9ABAQ38852654-8F59AD65-C7BE-402B-BED1-6B7006D6F5E1Q40074158-5F027034-1A5A-4C14-947A-C031FD742168Q46200255-5330AD40-F2DC-47FB-9B63-B4A043F8621EQ46479831-0A6EDAFA-6516-464E-876E-ACEC4FB17890Q47107885-C12C4731-1BF5-4B1D-A37A-4E51699FB3FDQ52323543-FDB0EAB3-94B8-414F-B997-C4AB54637425Q58595655-1136FA07-7CBA-4CF1-94A4-C192CA17C737
P2860
Disclosure of pharmacokinetic drug results to understand nonadherence
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Disclosure of pharmacokinetic drug results to understand nonadherence
@ast
Disclosure of pharmacokinetic drug results to understand nonadherence
@en
type
label
Disclosure of pharmacokinetic drug results to understand nonadherence
@ast
Disclosure of pharmacokinetic drug results to understand nonadherence
@en
prefLabel
Disclosure of pharmacokinetic drug results to understand nonadherence
@ast
Disclosure of pharmacokinetic drug results to understand nonadherence
@en
P2093
P2860
P1433
P1476
Disclosure of pharmacokinetic drug results to understand nonadherence
@en
P2093
Ariane van der Straten
Barbara Mensch
Cynthia I Grossman
Elizabeth T Montgomery
Helen Cheng
Jeanna Piper
Juliane Etima
Microbicide Trials Network-003D Study Team
Miriam Hartmann
P2860
P304
P356
10.1097/QAD.0000000000000801
P407
P577
2015-10-01T00:00:00Z